Quarterly Data (Unaudited) - Narratives (Details) - USD ($)			3 Months Ended								8 Months Ended	12 Months Ended
	Dec. 20, 2018	Jun. 11, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 01, 2018	Apr. 23, 2018
Interim Period, Costs Not Allocable
Severance costs												$ 3,200,000	$ 3,600,000	$ 8,600,000
Share-based compensation expense												4,900,000	10,600,000	10,100,000
Transaction related costs												2,100,000	10,100,000	400,000
Sales			$ 290,100,000	$ 272,200,000	$ 277,900,000	$ 244,100,000	$ 269,400,000	$ 202,700,000	$ 199,800,000	$ 171,000,000		1,084,300,000	842,900,000	722,000,000
Operating income (loss)			26,300,000	31,500,000	19,300,000	$ 15,000,000	20,900,000	7,200,000	$ 8,500,000	$ 1,900,000		92,100,000	38,500,000	41,000,000
Litigation Settlement, Expense							3,700,000
Loss on extinguishment of debt												0	4,900,000	0
Tax benefit from changes in enacted taxes							22,500,000					(1,300,000)	22,500,000
Provisional decrease of deferred tax liabilities							26,900,000						26,900,000
Provisional deemed repatriation transition tax							8,700,000					(3,800,000)	(8,700,000)
Convertible Debt | Convertible Notes, due 2018
Interim Period, Costs Not Allocable
Loss on extinguishment of debt							4,900,000					0	4,700,000	$ 0
Debt instrument, repurchase amount							192,900,000						192,900,000
Debt instrument face amount			0				57,100,000	$ 250,000,000			$ 0	0	57,100,000		$ 57,100,000.0
Debt instrument stated interest rate (percent)								2.00%							2.00%
VRV
Interim Period, Costs Not Allocable
Integration costs			800,000
Hudson
Interim Period, Costs Not Allocable
Transaction related costs													9,000,000
Sales							51,900,000	$ 6,100,000				180,300,000	58,000,000
Operating income (loss)							5,200,000	$ 1,200,000				19,000,000	6,400,000
Tax benefit from changes in enacted taxes							1,800,000
Provisional deemed repatriation transition tax							8,700,000						(8,700,000)
Additional tax expense related to merger							$ 4,500,000						$ 4,500,000
BioMedical | Disposed of by Sale
Interim Period, Costs Not Allocable
Gain on sale of business, net of taxes	$ 34,300,000		34,300,000									34,300,000
Employee severance
Interim Period, Costs Not Allocable
Severance costs												2,300,000
Share-based compensation expense				(900,000)	(1,800,000)
Employee severance | CEO
Interim Period, Costs Not Allocable
Severance costs		$ 1,400,000			1,400,000
Compensation forfeiture
Interim Period, Costs Not Allocable
Severance costs				$ 1,800,000	3,200,000
Product Warranty
Interim Period, Costs Not Allocable
Loss contingency accrual			100,000		$ 3,800,000						100,000	$ 100,000				$ 3,800,000
Provision for loss contingencies			$ 200,000								$ 200,000